Juan-Ignacio Mestre-Pinto
Barcelona, Catalonia, 08003, Spain
NCT Number: NCT04517474
Cannabis is the most widely used psychoactive substance around the world after alcohol and tobacco. Although approximately one in ten users develop serious problems of dependency, only a small number attend outpatient addiction counseling centers. CANreduce is an adherence-focused guidance enhanced web-based self-help program with promising results in German and other languages. It also reaches those users who hesitate to approach such treatment centers and help them to reduce their cannabis use.
This study will test the effectiveness of the Spanish version of the enhanced web-based self-help intervention with psychological support, an enhanced web-based self-help intervention (without psychological support) and a waiting list control in reducing cannabis use in problematic users.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Barcelona, Catalonia, 08003, Spain
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
CANreduce is an automated web-based self-help tool based on classical Cognitive Behavioral Treatment (CBT) approaches for treating cannabis dependence. It will consist of a consumption diary, eight modules designed to reduce cannabis use based on the principles of motivational interviewing, self-control practices, and methods of cognitive behavioral therapy ( strategies for goal achievement, Identifying risk situations, Dealing with cannabis craving, Dealing with relapses, Working on needs, Saying "no" to foster refusal skills, Dealing with burdens, Preserving achievements). Participants can study all modules at their own pace and order, though a specific order will be advised.
Other names: CANreduce: Adherence-focused guidance enhanced web-based self-help for the reduction of cannabis use with psychological support
psychological support
Time frame: Baseline, 6, 12 and 24 weeks.
Participants enter their cannabis consumption frequency into their consumption diary every week.
More days of self-reported cannabis use indicate worse state
Time frame: Baseline, 6, 12 and 24 weeks.
Participants enter their cannabis consumption frequency into their consumption diary every week.
More days of self-reported cannabis use indicate a worse outcome
Time frame: Baseline, 6, 12 and 24 weeks.
Participants enter their cannabis consumption quantity into their consumption diary every week.
More number of weekly standard joints indicate a worse outcome
Time frame: Baseline, 6, 12 and 24 weeks.
CUDIT-R was developed containing 8 items, two each from the domains of consumption, cannabis problems (abuse), dependence, and psychological features. It has excellent psychometric properties. High sensitivity (91%) and specificity (90%).
This questionnaire was designed for self administration and is scored by adding each of the 8 items:
Higher scores indicate a worse outcome
Time frame: Baseline, 6, 12 and 24 weeks.
SDS is a standard instrument to assess the severity to any drug dependence. Each of the five items is scored on a 4-point scale (0-3). The total score is obtained through the addition of the 5-item ratings (0-15). The higher the score the higher the level of dependence.
Time frame: Baseline, 6, 12 and 24 weeks.
AUDIT is a 10-item screening tool developed by the World Health Organization (WHO) to assess alcohol consumption, drinking behaviors, and alcohol-related problems. Each item scores 0-4, The total score ranges from 0-40. A score of 8 or more is considered to indicate hazardous or harmful alcohol use. The AUDIT has been validated across genders and in a wide range of racial/ethnic groups and is well suited for use in primary care settings. Higher scores indicate a worse outcome
Time frame: Baseline, 6, 12 and 24 weeks.
PROMIS (Patient-Reported Outcomes Measurement Information System) is a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children. It can be used with the general population and with individuals living with chronic conditions. Developed and validated with state-of-the-science methods to be psychometrically sound and to transform how life domains are measured.
8 items 1-5, score ranges 8-40 Higher scores indicate a worse outcome
Time frame: Baseline, 6, 12 and 24 weeks.
PROMIS (Patient-Reported Outcomes Measurement Information System) is a set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children. It can be used with the general population and with individuals living with chronic conditions. Developed and validated with state-of-the-science methods to be psychometrically sound and to transform how life domains are measured.
8 items 1-5, score ranges 8-40 Higher scores indicate a worse outcome
Time frame: Baseline, 6, 12 and 24 weeks.
EQ-5D-5L is a self-assessed, health related, quality of life questionnaire. The scale measures quality of life on a 5-component scale including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
Score ranges from less than 0 (where 0 is the value of a health state equivalent to dead; negative values representing values as worse than dead) to 1 (the value of full health),
The second part of the questionnaire consists of a visual analogue scale (VAS) on which the patient rates his/her perceived health from 0 (the worst imaginable health) to 100 (the best imaginable health).
Parc de Salut Mar
Other
Evaluación de Una Herramienta E-Salud Para la reducción Del Consumo de Cannabis
Acronym: CANREDUCE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06430580
Cannabis Use Disorder
Tallahassee, Florida, United States
View Trial DetailsNCT06920238
Anxiety, Anxiety Disorders
Lebanon, New Hampshire, United States
View Trial DetailsNCT06584942
Cannabis Use Disorder, Cue-reactivity
Boston, Massachusetts, United States
View Trial DetailsNCT06114212
Cannabis Use Disorder
Hamilton, Ontario, Canada
View Trial Details